Adulterated drugs: SC dismisses PIL against Ranbaxy

The Supreme Court on Tuesday dismissed a PIL against Ranbaxy. The court in its order said that there is no evidence to show that the pharma giant manufactured substandard drugs. The apex court also said that the petitioner failed to bring in evidence against Ranbaxy.

The PIL was filed against Ranbaxy for allegedly manufacturing and selling of the adulterated drug. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard and adulterated drugs. The pharma giant has been asked to pay a fine of 500 million dollars.

Ranbaxy has been facing the heat even in India with a few hospitals banning its drugs.

The PIL has also sought sealing of all Ranbaxy's manufacturing units in India, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.